Coronary Stents: Market Research Report

October 2011 | 396 pages | ID: CA83E20B8A8EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Coronary Stents in US$ Million and Thousand Units by the following Product Segments: Bare Metal Stents, and Drug Eluting Stents.

The report provides separate comprehensive analytics for the US, Japan, Europe, Asia Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2009 through 2017.

A six-year historic analysis is also provided for these markets.

The report profiles 53 companies including many key and niche players such as Angiotech Pharmaceuticals, Abbott Vascular, Biosensors International, Boston Scientific Corp., Cordis Corporation, Medtronic, Inc., Medtronic Cardiovascular, Inc., OrbusNeich, and Terumo Europe N.V.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Bare Metal Stents
Drug Eluting Stents

2. GLOBAL MARKET OVERVIEW

Growth Revives as Drug Eluting Stents Bounce Back
What’s Next on Cards in Coronary Stent Market?
Market Snapshots
Current and Future Analysis
Drug Eluting Stents Steal the Show
Star Player J&J to Quit DES Business in an Expensive Market Withdrawal

3. MARKET TRENDS AND ISSUES

Drug Eluting Stent System – Safety Concerns
Declining Prices – A Major Concern
Restenosis - the Real Growth Driver
Small Vessels – A Major Cause of Restenosis
Aging Population Propels Coronary Stent Market
Next Generation Stents – A Boon for Treating Coronary Diseases
Direct Stenting Systems Spur Growth
Drug Choice Impacts Market Entry
Threats to Coronary Stents – Alternative Therapies/Devices
Cell Transplantation – A Major Threat to Coronary Stents
Coronary Stents Market Challenged by Drug Therapy

4. COMPETITIVE ANALYSIS

Coronary Stents – Leading Players

Table 1. Leading Players in the Global Coronary Stents Market (2010 & 2012) – Percentage Breakdown of Market Share by Company - Boston Scientific, Abbott (Guidant), Johnson & Johnson, Medtronic, and Others (includes corresponding Graph/Chart)

Bare Metal Stents – Leading Players

Table 2. Leading Players in the Global Bare Metal Stents Market (2010) – Percentage Breakdown of Share for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart)

Drug-Eluting Stents – Leading Players

Table 3. Global Drug Eluting Stents Market (2010): Percentage Breakdown of Share by Company - Boston Scientific, Abbott Labs, Johnson and Johnson, Medtronic, Others (includes corresponding Graph/Chart)

Major DES Types in the Market and Leading Manufacturers
Comparative Analysis of the Leading Players

5. CORONARY DISEASE - A PERSPECTIVE

Factors Responsible for Coronary Diseases
Controllable Risk Factors
High Blood Cholesterol
Sedentary Life Style and Habits
Smoking Habits
High Blood Pressure
Uncontrollable Risk Factors
Age
Heredity
Gender
Causative Risk Factors
Stress and Anger
Obesity
Diabetes
Symptoms of Coronary Artery Disease
Diagnosis
Treatment
Drug Supported Treatments
Invasive Treatments
Bypass Surgery
Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty)
Natural Therapy
Coronary Angioplasty Suitable for Acute Myocardial Infarction
Advancements in Coronary Disease Treatment Modalities
University of Virginia’s Microbe Solution for Post Surgical Complications
Radiation for Re-clogged Arteries Show Promise
Radioactive Coronary Stents Promise Bright Future

6. CORONARY STENTS - PRODUCT OVERVIEW

Introduction
Evolution of Coronary Stents
Applications of Coronary Stents
Stent Deployment
Key Stent Delivery Platforms by Select Company
Coronary Stent Designs
Key Factors Determining Coronary Stent Performance
Delivery Convenience
Efficient Scaffolding
Radiopacity (Visibility)
Optimum Flexibility
Shape Conformability
Material for Coronary Stent
Risk Associated with Stenting
Improper Stent Implantation Likely Cause for In-Stent Restenosis
Precautions
Direct Coronary Stenting – Creating an Enliven
Limitations
Regulatory Approvals Wooing Stent Market
A Peek into Regulatory Approvals for Coronary Stents

7. PRODUCT SEGMENTS

Bare Metal Stents
Major Bare Metal Stents by Company
Drug-Eluting Stents
DE Stents Overshadow Intravascular Brachytherapy Interventions
Major Drug-Eluting Stents by Company
Drugs for Coating DESs
Cytotoxic or Cytostatic Drug – the Debate Continues
Dosing and Deliverability Crucial for DES
Polymer Coatings for Effective Dosing and Deliverability
Drugs Used for DES by Major Competitors in the Stent Market
Leading Coronary Stent Brands
Cypher
Structure and Delivery Mechanism
Taxus
Structure and Delivery Mechanism

8. RESEARCH AND DEVELOPMENT

Extensive R&D Underway in Global Drug-Eluting Stents Market
At the Labs
Other Products Under Trials – A Recent Past Perspective
OMT Developing R-stent
Reva Developing Stainless Steel Bare-Metal Stent
D&P Corp Developing Bovine Pericardium- Covered Stent
Advanced Bio Synthesizing Porous Drug-Eluting Stents
Lombard Medical Developing PEP Coatings
Shiga Develops Biodegradable Drug-Eluting Stent

9. PRODUCT INNOVATIONS/INTRODUCTIONS

Boston Scientific Launches ION™ Platinum Chromium Stent System
Terumo Introduces Nobori Drug-Eluting Coronary Stent
Boston Scientific Unveils TAXUS® Element™ and PROMUS® Element™ Stent Systems
Covidien Introduces EverFlex+™ Self-Expanding Peripheral Stent System
Boston Scientific Launches Taxus Element Stent System in European Union
Cordis Introduces PRESILLION™ PLUS Stent System in Europe
Medtronic Launches Resolute Integrity Stent System
InspireMD Unveils MGuard Prime
Boston Scientific Introduces Taxus Eluting Stent System
Boston Scientific Unveils TAXUS Liberte Paclitaxel Eluting Stent System in Japan
Alvimedica Launches Coracto Drug-Eluting Stent in Europe
Abbott Labs to Launch XIENCE V in China
Medtronic Launches Driver Sprint RX Coronary STENT System
Existent Introduces Premier Coronary Stent System
Medtronic to Unveil Balloon Catheter Systems and Coronary Stents
NanoInterventions Launches Mouse Stent Model
InspireMD - MGuard™ Coronary Stent Launched in Italy
CeloNova BioSciences Launches CATANIA™ Coronary Stent with NanoThin Polyzene®-F
Angiotech Launches Cook Medical’s Drug Eluting Zilver® PTX™ Stent in New Zealand

10. RECENT INDUSTRY ACTIVITY

Boston Scientific Receives FDA Approval for Novel Paclitaxel-Eluting Coronary Stent
Boston Scientific Receives Approval for Distribution of PROMUS® Everolimus-Eluting Stent
Cordis Discontinues Production of NEVO™ Sirolimus- Eluting Coronary Stents
Boston Scientific Receives FDA Approval for ION Stent
Abbott Obtains FDA Approval to Extend RX ACCULINK® Carotid Stent System Application
Boston Scientific Receives CE Mark Approval for OMEGA™ Platinum Chromium Stent System
Stentys Launches Stents across Additional Countries in Europe
Opto Circuits Acquires N. S. Remedies
Biosensors International Group Takes Over Assets of Devax
Cordis Signs Distribution Agreement with Ostial Solutions
Medtronic Obtains FDA Approval for Integrity Coronary Stent System
Boston Scientific Receives Approval from Japanese MHLW for PROMUS® Coronary Stent
InspireMD Selects Kirloskar Technologies for Distributing Coronary Stent Systems
Boston Scientific Expands PROMUS® Everolimus-Eluting Coronary Stent System
Boston Scientific Receives TGS Approval from Australia
Svelte Medical Systems Commences Clinical Trial of SOAW Delivery System
Abbott Receives Japan's MHLW Approval for Xience V
Opto Circuits Receives Mark Approval from Communite European
Abbott Receives Health Canada Approval for XIENCE V® Stent System
Medtronic Secures Japan's MHLW Approval for Endeavor® Drug Eluting Stent
Boston Scientific Takes Over Labcoat
Micell and Maxcor Sign Strategic Agreement
Cordis Receives FDA Approval for Variant of Cypher Sirolimus-Eluting Coronary Stent
Boston Scientific Obtains CE Mark Approval for Promus Element Everolimus-Eluting Coronary Stent System
Cypher Select® Plus Sirolimus-eluting Coronary Stent Gains CE Mark for Treatment in Diabetic Patients
Atrium Medical Obtains CE Mark for Cinatra™
Medtronic Secures CE Mark Approval for Endeavor Drug-Eluting Stent for Use in Treatment of ACS
CorNova® Obtains CE mark approval for Valecor Platinum Coronary Stent System
Cook Medical Receives CE Mark Approval and Launches Zilver® PTX® Drug-Eluting Peripheral Stent
Disa Receives CE Approval for Coronary Stent
Datascope Acquires Peripheral Stent Business of Sorin Group
Boston Scientific Receives FDA approval for TAXUS® Liberte® Drug-Eluting STENT
Abbott Labs Receives FDA Approval for Xience V
Bard to Purchase Assets of LifeStent Product Portfolio
Medtronic Receives the US FDA Approval to Use Endeavor® Stent
Medtronic Inc. Receives Approval for its Drug-Eluting Stent, “Endeavor” In Canada
Boston Scientific to Market TAXUS® Liberte® Stent System in Canada
Abbott Applies for Approval of XIENCE™ V in Japan
Medinol Achieves CE Mark Approval for Presillion™ Cobalt Chromium Coronary Stent System
Iberhospitex Receives Spanish Approval to Sell Palau Pharma’s “Active” Coronary Stent
Clearstream’s Intrepide Drug Eluting Stent of Clearstream Receives CE mark approval
Terumo Introduces Its Drug-Eluting Stent in Germany and Marks Its European Entry
Tryton Medical’s Side-Branch Stent Achieves CE Mark Approval
CV Therapeutics Offers its Stent Coating Technology to Medlogics Device Corporation
Abbott’s 2. 25mm-Sized XIENCE™ V Drug Eluting Stent receives CE Mark of Approval
Biosensors Receives CE Mark Approval for BioMatrix® Stent System
Nfocus Neuromedical’s CardioVasc™ Stent-Graft and Delivery System Receives CE Mark Approval

11. FOCUS ON SELECT GLOBAL PLAYERS

Angiotech Pharmaceuticals (Canada)
Abbott Vascular (USA)
Biosensors International (USA)
Boston Scientific Corp. (USA)
Cordis Corporation (JNJ) - (USA)
Medtronic, Inc. (USA)
Medtronic Cardiovascular, Inc. (USA)
OrbusNeich (Hong Kong)
Terumo Europe N. V. (Belgium)

12. GLOBAL MARKET PERSPECTIVE

Table 4. World Recent Past, Current & Future Analysis for Coronary Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 5. World Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 6. World Historic Review for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 7. World Historic Review for Coronary Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 8. World 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 9. World 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 10. World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 11. World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 12. World Historic Review for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 13. World Historic Review for Coronary Stents by Product Segment–Bare Metal Stents and Drug Eluting Stents Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 14. World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 15. World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 16. World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 17. World Recent Past, Current & Future Analysis for Bare Metal Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 18. World Historic Review for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sale sin US$ Million for Years 2003 through 2008(includes corresponding Graph/Chart)

Table 19. World Historic Review for Bare Metal Stents By Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 20. World 15-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 21. World 15-Year Perspective for Bare Metal Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 22. World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 23. World Recent Past, Current & Future Analysis for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia – Pacific (Excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 24. World Historic Review for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 25. World Historic Review for Drug Eluting Stents by Geographic Region – US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets Independently Analyzed with Annual Sales in Thousand Units for Years 2003 through 2008 (includes corresponding Graph/Chart)

Table 26. World 15-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 27. World 15-Year Perspective for Drug Eluting Stents by Geographic Region – Percentage Breakdown of Unit Sales for US, Japan, Europe, Asia-Pacific (Excluding Japan) and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

13. THE UNITED STATES

A. Market Analysis
Largest Market Worldwide
Coronary Artery Disease - A US Perspective
Baby Boomers Boost Coronary Stent Market
Revival in the DES Market
Reimbursement System
National Average Medicare Payment For DRGS
Competitive Scenario
Leading Players
Coronary Stents – Boston Scientific and JNJ Battle for Dominance

Table 28. Leading Players in the US Coronary Stents Market (2010) – Percentage Breakdown of Share for Boston Scientific, Abbott and Johnson & Johnson (includes corresponding Graph/Chart)

Drug Eluting Stents – Competition in the Brewing

Table 29. Leading Players in the US Drug-Eluting Stents Market (2010) – Percentage Breakdown of share for Boston Scientific, Abbott Labs, J&J-Cordis and Medtronic (includes corresponding Graph/Chart)

Regulatory Environment
B. Market Analytics

Table 30. US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 31. US Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 32. US Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 33. US Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 34. US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 35. US 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

14. JAPAN

A. Market Analysis
Prospects Weighed down by Regulatory Entanglements
Japanese Coronary Stents Command Higher Prices

Table 36. Coronary Stent Pricing (2008): Comparative Analysis of Prices in Japan, US, Europe and Global Average (includes corresponding Graph/Chart)

Competitive Landscape

Table 37. Leading Players in the Japanese Coronary Stent Market ( 2010) – Percentage Breakdown of Share for Johnson & Johnson, Medtronic, Boston Scientific, and Others (includes corresponding Graph/Chart)

Table 38. Leading Players in the Japanese Bare Metal Stent Market (2010) – Percentage Breakdown by of Share for Medtronic, Boston Scientific, JNJ and Others (includes corresponding Graph/Chart)

Table 39. Leading Players in Japanese Drug-Eluting Stent Market (2010) – Percentage Breakdown of Share for Johnson & Johnson and Boston Scientific (includes corresponding Graph/Chart)

B. Market Analytics

Table 40. Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 41. Japanese Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 42. Japanese Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 43. Japanese Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 44. Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 45. Japanese 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15. EUROPE

A. Market Analysis
Cardiovascular Disease in Europe – A Perspective
Growth Bar Too Low
Two-Speed Europe
Stent Market’s Merger Mania
Dampeners to Rapid Adoption of DES in Europe
Competitive Scenario

Table 46. Leading Players in the European Drug- Eluting Stent Market (2010) – Percentage Breakdown of Share for Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 47. European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 48. European Recent Past, Current & Future Analysis for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years2009 through 2017 (includes corresponding Graph/Chart)

Table 49. European Historic Review for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 50. European Historic Review for Coronary Stents by Geographic Region – France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 51. European 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 52. European 15-Year Perspective for Coronary Stents by Geographic Region – Percentage Breakdown of Unit Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2003, 2010 & 2075 (includes corresponding Graph/Chart)

Table 53. European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 54. European Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stents Markets Independently Analyzed with Annual sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 55. European Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 56. European Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 57. European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 58. European 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15A. FRANCE

Market Analysis

Table 59. French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 60. French Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 61. French Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 62. French Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 63. French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 64. French 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15B. GERMANY

Market Analysis

Table 65. German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 66. German Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 67. German Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 68. German Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 69. German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 70. German 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15C. ITALY

Market Analysis

Table 71. Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)

Table 72. Italian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 73. Italian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 74. Italian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 75. Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 76. Italian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15D. THE UNITED KINGDOM

Market Analysis

Table 77. UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 78. UK Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 79. UK Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 80. UK Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 81. UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 82. UK 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15E. SPAIN

Market Analysis

Table 83. Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 84. Spanish Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 85. Spanish Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 86. Spanish Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 87. Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 88. Spanish 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15F. RUSSIA

Market Analysis

Table 89. Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 90. Russian Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 91. Russian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 92. Russian Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 93. Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 94. Russian 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

15G. REST OF EUROPE

Market Analysis

Table 95. Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 96. Rest of Europe Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 97. Rest of Europe Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 98. Rest of Europe Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 99. Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 100. Rest of Europe 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

16. ASIA-PACIFIC

A. Market Analysis
China – Healthcare Reforms to Propel DES Market

Table 101. Coronary Stent Market in China (2010): Percentage Breakdown of Market Share by Company- Shanghai Microport, Beijing Lepu, JW Medical, J&J Cordis, Medtronic and Others (includes corresponding Graph/Chart)

Coronary Stent Market in a Bubble Zone Now
Regional Players and their DES Development Efforts
Cost Focus Helps Stent Makers Win the Market Stunt
B. Market Analytics

Table 102. Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 103. Asia-Pacific Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 104. Asia-Pacific Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008(includes corresponding Graph/Chart)

Table 105. Asia-Pacific Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008(includes corresponding Graph/Chart)

Table 106. Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 107. Asia-Pacific 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

17. REST OF WORLD

A. Market Analysis
Brazil – Low Penetration of DES
South Africa – Leading Players

Table 108. Leading Players in South African Coronary Stent Market (2010) – Percentage Breakdown by Unit Sales for Johnson & Johnson, Boston Scientific, Guidant, Abbott and Others (includes corresponding Graph/Chart)

B. Market Analytics

Table 109. Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 110. Rest of World Recent Past, Current & Future Analysis for Coronary Stents by Product Segment – Bare Metal Stent and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2009 through 2017 (includes corresponding Graph/Chart)

Table 111. Rest of World Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in US$ Million for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 112. Rest of World Historic Review for Coronary Stents by Product Segment – Bare Metal and Drug Eluting Stent Markets Independently Analyzed with Annual Sales in Thousand Units for years 2003 through 2008 (includes corresponding Graph/Chart)

Table 113. Rest of World 15-Year Perspective for Coronary Stents by Product Segment – Percentage Breakdown of Dollar Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

Table 114. Rest of World 15-Year Perspective for Coronary Stents by Product Segment - Percentage Breakdown of Unit Sales for Bare Metal Stents and Drug Eluting Stents Markets for years 2003, 2010 & 2017 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Total Companies Profiled: 53 (including Divisions/Subsidiaries - 62)
Region/CountryPlayers
The United States34
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Africa